Hal Siegel provides extensive scientific affairs expertise as the Senior Director of Medical and Scientific Affairs at Imaging Endpoints. Previous positions have included Vice President and FDA liaison at ImmuneRegen BioSciences (IRBS) and Zila, Inc., Chief Scientific Officer at New Amsterdam Sciences, consultant to multiple life science and IT companies and senior management at an FDA-regulated SaaS startup. His experience includes compliance and audit oversight on software and medical product development, vendor management, product labeling, and educational and promotional media regulations. He was responsible at IRBS for directing a multi-million dollar pre-clinical development program, and subsequently, at New Amsterdam Sciences, directed the development of both pre-clinical and clinical acquisitions. He has authored a successful Orphan Drug application as well as dozens of CDER, CBER, or CDRH submissions and interactions involving INDs, NDAs, 510(k)s, PMAs, Master Files, Advisory Committee or pre-IND/NDA/PMA meetings. He holds RAC certification (1999) and is (co)/holder of 7 US patents. Hal received his Ph.D. in Biochemical Pharmacology, SUNY Buffalo, NY.